Akash Tewari
Stock Analyst at Jefferies
(2.27)
# 2,769
Out of 5,055 analysts
61
Total ratings
40%
Success rate
1.08%
Average return
Main Sectors:
Stocks Rated by Akash Tewari
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TERN Terns Pharmaceuticals | Maintains: Buy | $28 → $35 | $22.56 | +55.14% | 2 | Nov 3, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Buy | $83 → $96 | $71.55 | +34.17% | 2 | Sep 2, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $813 → $831 | $693.50 | +19.83% | 5 | Aug 27, 2025 | |
| CBIO Crescent Biopharma | Initiates: Buy | $26 | $13.03 | +99.62% | 1 | Aug 25, 2025 | |
| ARVN Arvinas | Downgrades: Hold | $52 → $10 | $10.57 | -5.39% | 3 | May 2, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Buy | $70 → $68 | $46.65 | +45.77% | 4 | Apr 23, 2025 | |
| BMRN BioMarin Pharmaceutical | Initiates: Outperform | $95 | $54.73 | +73.58% | 2 | Nov 15, 2024 | |
| BNTX BioNTech SE | Upgrades: Buy | $96 → $150 | $103.09 | +45.50% | 3 | Sep 17, 2024 | |
| RLAY Relay Therapeutics | Upgrades: Buy | $11 → $16 | $6.29 | +154.37% | 3 | Sep 10, 2024 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $177 → $189 | $144.86 | +30.47% | 2 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 | $20.33 | +293.51% | 2 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $994 → $1,015 | $1,025.28 | -1.00% | 6 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $50 | $29.04 | +72.18% | 6 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $37 → $75 | $65.50 | +14.50% | 4 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $31 | $23.50 | +31.91% | 1 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $38 → $39 | $25.06 | +55.63% | 2 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $49 → $18 | $12.05 | +49.38% | 2 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $497 → $513 | $907.98 | -43.50% | 2 | Jul 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $125 | $92.92 | +34.52% | 1 | Mar 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $7.7 → $11 | $18.52 | -40.60% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $17 | $2.24 | +658.93% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $66.44 | +12.88% | 2 | Oct 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $151 | $529.21 | -71.47% | 1 | Oct 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $41.65 | -32.77% | 3 | Oct 7, 2021 |
Terns Pharmaceuticals
Nov 3, 2025
Maintains: Buy
Price Target: $28 → $35
Current: $22.56
Upside: +55.14%
Ionis Pharmaceuticals
Sep 2, 2025
Maintains: Buy
Price Target: $83 → $96
Current: $71.55
Upside: +34.17%
Regeneron Pharmaceuticals
Aug 27, 2025
Maintains: Buy
Price Target: $813 → $831
Current: $693.50
Upside: +19.83%
Crescent Biopharma
Aug 25, 2025
Initiates: Buy
Price Target: $26
Current: $13.03
Upside: +99.62%
Arvinas
May 2, 2025
Downgrades: Hold
Price Target: $52 → $10
Current: $10.57
Upside: -5.39%
Bristol-Myers Squibb Company
Apr 23, 2025
Maintains: Buy
Price Target: $70 → $68
Current: $46.65
Upside: +45.77%
BioMarin Pharmaceutical
Nov 15, 2024
Initiates: Outperform
Price Target: $95
Current: $54.73
Upside: +73.58%
BioNTech SE
Sep 17, 2024
Upgrades: Buy
Price Target: $96 → $150
Current: $103.09
Upside: +45.50%
Relay Therapeutics
Sep 10, 2024
Upgrades: Buy
Price Target: $11 → $16
Current: $6.29
Upside: +154.37%
Neurocrine Biosciences
Aug 19, 2024
Maintains: Buy
Price Target: $177 → $189
Current: $144.86
Upside: +30.47%
Jul 31, 2024
Maintains: Buy
Price Target: $80
Current: $20.33
Upside: +293.51%
Jun 24, 2024
Maintains: Buy
Price Target: $994 → $1,015
Current: $1,025.28
Upside: -1.00%
Apr 9, 2024
Maintains: Buy
Price Target: $42 → $50
Current: $29.04
Upside: +72.18%
Mar 6, 2024
Maintains: Buy
Price Target: $37 → $75
Current: $65.50
Upside: +14.50%
Dec 11, 2023
Initiates: Buy
Price Target: $31
Current: $23.50
Upside: +31.91%
Oct 16, 2023
Upgrades: Buy
Price Target: $38 → $39
Current: $25.06
Upside: +55.63%
Aug 8, 2023
Downgrades: Hold
Price Target: $49 → $18
Current: $12.05
Upside: +49.38%
Jul 17, 2023
Maintains: Buy
Price Target: $497 → $513
Current: $907.98
Upside: -43.50%
Mar 6, 2023
Initiates: Buy
Price Target: $125
Current: $92.92
Upside: +34.52%
Dec 20, 2022
Upgrades: Buy
Price Target: $7.7 → $11
Current: $18.52
Upside: -40.60%
Dec 12, 2022
Initiates: Buy
Price Target: $17
Current: $2.24
Upside: +658.93%
Oct 7, 2021
Initiates: Buy
Price Target: $75
Current: $66.44
Upside: +12.88%
Oct 7, 2021
Initiates: Buy
Price Target: $151
Current: $529.21
Upside: -71.47%
Oct 7, 2021
Initiates: Buy
Price Target: $28
Current: $41.65
Upside: -32.77%